Prometheus Biosciences Inc

US

Health Care

199.92 ₽

Current price

Strong sell
199.92 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    884 / 1361

  • Position in country

    11897 / 14179

  • Return on Assets, %

    -40.6

    -40.3

  • Net income margin, %

    -3699.2

    -180

  • EBITDA margin, %

    -4386.6

    -168.2

  • Debt to Equity, %

    0

    3.2

  • Intangible assets and goodwill, %

    0

    0.2

  • Revenue CAGR 3Y, %

    82.6

    12.5

  • Total Equity change 1Y, %

    3.2

    -9

  • Revenue Y, % chg

    -41.4

    0

  • P/BV

    13.8

    1.8

  • EV/EBITDA

    -30.4

    -1.6

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Moderna Inc

    00%

  • Alnylam Pharmaceuticals Inc

    00%

  • AbbVie Inc

    00%

  • Biogen Inc

    00%

  • Prometheus Biosciences Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    9558.8

  • Ticker

    RXDX.O

  • ISIN

    US74349U1088

  • IPO date

  • Availability on Russian exchanges

    No

  • Reporting for

    2023-05-09

  • Date fact. publication of reports

    2023-03-31

Company Description

Prometheus Biosciences, Inc. is a biotechnology company. The Company is engaged in the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). Its precision medicine platform Prometheus360, which includes gastrointestinal (GI) bioinformatics databases, to identify therapeutic targets and develop therapeutic candidates to engage the targets. The Company's product pipeline includes PRA023, PR600, PR300, PR1800 and PR2100. Its lead product candidate PRA023, is an IgG1 humanized monoclonal antibody (mAb) designed to target both inflammation and fibrosis associated with IBD. It has focused on developing PRA023 for the treatment of UC and Crohn’s disease (CD).

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: